Your browser doesn't support javascript.
loading
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj, Maria; Scarfò, Irene; Cabral, Maria L; Bailey, Stefanie R; Lorrey, Selena J; Bouffard, Amanda A; Castano, Ana P; Larson, Rebecca C; Riley, Lauren S; Schmidts, Andrea; Choi, Bryan D; Andersen, Rikke S; Cédile, Oriane; Nyvold, Charlotte G; Christensen, Jacob H; Gjerstorff, Morten F; Ditzel, Henrik J; Weinstock, David M; Barington, Torben; Frigault, Matthew J; Maus, Marcela V.
Afiliación
  • Ormhøj M; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Scarfò I; Department of Clinical Immunology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
  • Cabral ML; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Bailey SR; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Lorrey SJ; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Bouffard AA; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Castano AP; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Larson RC; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Riley LS; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Schmidts A; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Choi BD; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Andersen RS; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
  • Cédile O; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Nyvold CG; Haematology-Pathology Research Laboratory, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
  • Christensen JH; Department of Pathology, Odense University Hospital, Odense, Denmark.
  • Gjerstorff MF; OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.
  • Ditzel HJ; Haematology-Pathology Research Laboratory, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
  • Weinstock DM; Department of Pathology, Odense University Hospital, Odense, Denmark.
  • Barington T; OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark.
  • Frigault MJ; Department of Haematology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
  • Maus MV; Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Clin Cancer Res ; 25(23): 7046-7057, 2019 12 01.
Article en En | MEDLINE | ID: mdl-31439577
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T / Inmunoterapia Adoptiva / Antígenos CD19 / Linfoma de Células del Manto / Antígenos CD79 / Receptores Quiméricos de Antígenos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T / Inmunoterapia Adoptiva / Antígenos CD19 / Linfoma de Células del Manto / Antígenos CD79 / Receptores Quiméricos de Antígenos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article